Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Latest Information Update: 20 Jun 2019
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 18 Jun 2019 Status changed from active, no longer recruiting to completed.
- 26 Feb 2019 Planned End Date changed from 31 Jan 2020 to 9 May 2019.
- 26 Feb 2019 Status changed from recruiting to active, no longer recruiting.